In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice

International Journal of Cancer

Volumn 75, Issue 6, 1998, Pages 908-918

  Riedle, Sandra ^a   Rösel, Marc ^a   Zöller, Margot ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY CD3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA CELL; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CD4-CD8 RATIO; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 2642670289     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980316)75:6<908::AID-IJC14>3.0.CO;2-Z     Document Type: Article

References (29)

1. ARNOLD, B., HORSTMANN, U., KUON, W., BURGERT, H.G., HAMMERLING, G.L. and KVIST, S., Alloreactive cytolytic T-cell clones preferentially recognize conformational determinants on histocompatibility antigens: analysis with genetically engineered hybrid antigens. Proc. nat. Acad. Sci. (Wash.), 82, 7030-7037 (1985).
2. BAKACS, T., LEE, J., MURENO, M.B., ZACHARCHUK, C.M., COLE, M.S., TSO, J.Y., PAIK, C.H., WARD, J.M. and SEGAL, D.M., A bi-speciric antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma. Int. Immunol., 7, 947-955 (1995).
3. BECKER, J.C., PANCOOK, J.D. GILLIES, S.D., MENDELSOHN, J.M. and REISFELD, R.A., Eradiaction of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-intcrlcukin-2 fusion proteins. Proc. nat. Acad. Sci. (Wash.), 93, 2702-2707 (1996).
4. BELANI, R. and WEINER, G.J., T-cell activation and cytokine production in anti-CD3 bi-specific-antibody therapy. J. Hematother., 4, 395-402 (1995).
5. BYERS, V.S. and BALDWIN, R.W., Rationale for clinical use of immunotoxins in cancer and autoimmune disease. Semin. Cell. Biol., 2, 59-70 (1992).
6. CANEVARI, S., MEZZANZANICA, D., MAZZONI, A., NEGRI, D.R., RAMAKRISHNA, V., BOLHUIS, R.L., COLNAGHI, M.I. and Bous, G., Bi-specificantibody targeted T-cell therapy of ovarian cancer: clinical results and future directions. J. Hematother., 4, 423-427 (1995).
7. CARREL, S., DORE, J.F., RUITER, D.J., PRAD, M., LEJEUNE, F.J., KLEEBERG, U.R., RUMKE, P. and BROCKER, E.B. The EORTC melanoma group exchange program: evaluation of a multicenter monoclonal antibody study. Int. J. Cancer, 48, 836-847, (1991).
8. CAVALLO, F., MARTIN-FONTECHA, A., BELLONE, M., HELTAI, S., GATTI, E., TORNAGHI, P., FRESCHI, M., FORNI, G., DELLABONA, P. and CASORATI, G., Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Europ. J. Immunol., 25, 1154-1162 (1995).
9. 2 bifunctional antibody activates and re-targets tumor-infiltrating lymphocytes. J. Immunol., 155, 1296-303 (1995).
10. DE GAST, G.C., VAN HOUTEN, A.A., HAAGEN, I.A., KLEIN, S., DE WEGER, R.A., VAN DIJK, A., PHILLIPS, J., CLARK, M. and BAST, B.J., Clinical experience with CD3 × CD19 bi-specific antibodies in patients with B-cell malignancies. J. Hematother., 4, 433-437 (1995).
11. DEMANET, C., BRISSINCK, J., DE JONGE, J. and THIELEMANS, K., Bi-specific-antibody-mediated immunotherapy of the BCL-1 lymphoma: increased efficacy with multiple injections and CD28-induced co-stimulation. Blood, 87, 4390-4398 (1996).
12. DOHLSTEN, M., HANSSON, J., OHLSSON, L., LITTON, M. and KALLAND, T., Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc. nat. Acad. Sci. (Wash.), 92, 9791-9795 (1995).
13. FRYTAK, S., CREAGAN, E.T., BROWN, M.L., SALK, D. and NELP, W., A technitium-labeled monoclonal antibody for imaging metastatic melanoma. Amer. J. clin. Oncol., 14, 156-161 (1991).
14. HAAGEN, I.A., DELAU, W.B., BAST, B.J., GEERARS, A.J., CLARK, M.R. and DEGAST, B.C. Unprimed CD4+ and CD8+ T cells can be rapidly activated by CD3 × CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol. Immunother., 39, 391-396 (1994).
15. HARADA, M., OKAMOTO, T., OMOTO, K., TAMADA, K., TAKENOYAMA, M., HIRASHIMA, C., ITO, O., KIMURA, G. and NOMOTO, K., Specific immunotherapy with tumour-draining lymph-node cells cultured with both antiCD3 and anti-CD28 monoclonal antibodies. Immunology, 87, 447-453 (1996).
16. IFERSEN, P., MARTENSSON, C., DANIELSON, L., INGVAR, C., CARLSSON, R. and BORREBAECK, C. A., Induction of primary antigen-specific immune response in SCID-hu-PBL by coupled T-B epitopes. Immunology 84, 111-116 (1995).
17. JUNG, G., FREIMANN, U., VON MARSCHALL, Z., REISFELD, R.A. and WILMANN, W., Target-cell-induced T-cell activation with bi- and tri-specific antibody fragments. Europ. J. Immunol., 21, 2431-2435 (1991).
18. KROESEN, B.J., BAKKER, A., VAN LIER, R.A., THE, H.T. and DE LEU, L., Bi-specific-antibody-mediated target-cell-specific co-stimulation of resting T cells via CD5 and CD28, Cancer Res., 55, 4409-4415 (1995).
19. MAEURER, M.J., STORKUS, W.J., KIRKWOOD, J.M. and LOTZE, M.T., New treatment options for patients with melanoma: review of melanoma-derived T-cell-epitope-based peptide vaccines. Melanoma Res., 6, 11-24 (1996).
20. MATZKU, S., BROCKER, E.B., BRUGGEN, J,. DIPPOLD, W.G. and TILGEN, W., Modes of binding and internalization of monoclonal antibodies to human melanoma cell lines. Cancer Res., 46, 3848-3854 (1986).
21. MISCHER, G.C., SCHREYER, M. and MACDONALD, H.R., Production and characterization of a rat monoclonal antibody against the murine CD3 molecular complex. Immunol. Lett., 23, 113-118 (1989).
22. MORTON, D.L. and BARTH, A., Vaccine therapy for malignant melanoma. CA (N.Y.); 46, 225-244 (1996).
23. MUKHERJI, B. and CHAKRABORTY, N.G., Immunobiology and immunotherapy of melanoma. Curr. Opin. Oncol., 7, 175-184 (1995).
24. PARMIANI, G. and COLOMBO, M.P., Somatic gene therapy of human melanoma: pre-clinical studies and early clinical trials. Melanoma Res., 5, 295-301 (1995).
25. ROSESBERG, S.A., The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Ann. Rev. Med., 47, 481-491 (1996).
26. SHPITZ, B., FERNANDES, B.J., MULLEN, J.B., RODER, J.C. and GALLINGER, S., Improved engraftment of human tumours in SCID mice pre-treated with radiation and anti-asialo GM1. Anticancer Res., 14, 1927-1934 (1994).
27. STRVENSON, G.T., BELL, A.J., EVANS, T.R., FRENCH, R.R., GLENNIE, M.J., HAMBLIN, T.J., KAN, K.S. and MEAD, G.M., Mechanisms in removal of tumor by antibody. Cell. Biophys., 24-25, 45-50 (1994).
28. THIELEMANS, K.M., Immunotherapy with bispecific antibodies. Verh. K. Acad. Geneeskd. Belg., 57, 229-247 (1995).
29. VAN MUIJEN, G.N.P., CORNELISSEN, L.M.A.H., JANSEN, C.F.J., FIGDOR, C.G., JOHNSON, J.P., BROCKER, E.B. and RUITER, D.J., Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin. exp Metast., 9, 259-272 (1991).